NCT05721612

Titanium Platelet-rich Fibrin in Sinus Floor Elevation Through Flapless Transcrestal Approach

Completed NA Last updated 21 February 2023

What this trial tests

NA trial testing Flapless transcrestal sinus lift approach with TPRF in Sinus Floor Elevation in 16 participants. Completed in 5 February 2023.

Timeline

15 March 2022

Primary endpoint
30 January 2023

5 February 2023

Quick facts

Lead sponsor	Hams Hamed Abdelrahman
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	16
Start date	15 March 2022
Primary completion	30 January 2023
Estimated completion	5 February 2023
Sites	1 location across Egypt

Drugs / interventions tested

• Flapless transcrestal sinus lift approach with TPRF
• Flapless transcrestal sinus lift approach with PRF

Conditions studied

• Sinus Floor Elevation — all drugs for Sinus Floor Elevation →

Sponsor

Hams Hamed Abdelrahman — full company profile →

Who can join

Adults 25 to 60, any sex, with Sinus Floor Elevation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dental implant therapy in the posterior maxilla may be difficult owing to limited bone height after dental extraction with sinus pneumatization. Several approaches for sinus floor elevation have been documented, and hence flapless transcrestal sinus floor elevation is minimally invasive technique which is used in moderately defected maxilla.

Aim of the study: to evaluate both clinical and radiographic outcomes in sinus floor elevation following dental implant placement using flapless transcrestal sinus lift approach with Titanium platelet rich fibrin (TPRF) as a sole sinus graft material compared to Platelet rich fibrin (PRF).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.